
|Podcasts|December 3, 2021
Pharmacy Focus: Psychedelic Pharmacy - Episode 2
Payton Nyquvest, CEO and founder of Numinus, discussed the laboratory development and regulatory side of psychedelic research.
Advertisement
In the second episode of the Psychedelic Pharmacy series, Payton Nyquvest, CEO and founder of Numinus, discussed the laboratory development and regulatory side of psychedelic research. In the interview, Nyquvest said he believes psychedelics will lead to a major shift in the mental health treatment paradigm in the next 3 to 5 years.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Transforming HER2+ Metastatic Breast Cancer Treatment With Targeted ADC Therapy
2
Emerging Biomarkers Open New Frontiers in Lung Cancer Therapy
3
Dato-DXd Doubles Response Rates and Extends Survival in First-Line Metastatic TNBC
4
Targeted α-Particle Radioligand Therapy Shows Promising Activity, Low Toxicity in SSTR2-Positive Neuroendocrine Tumors
5